Research Article

Effects of Polymorphisms in Myc-Related Genes on Bleeding Complications in Patients with Stable Warfarin Responses

Table 2

Factors associated with bleeding complications at a therapeutic INR.

Gene polymorphismAllele changeMinor allele frequencyGrouped genotypesBleeding complications, number (%)OR (95% CI)P
Presence 
(n = 21)
Absence 
(n = 121)

VKORC1 C>T0.113CC, CT3 (14.3)27 (22.3)10.405
 rs9934438TT18 (85.7)94 (77.7)1.72 (0.47-6.29)
CYP2C9 A>C0.043AA18 (85.7)111 (92.5)10.304
 rs1057910AC, CC3 (14.3)9 (7.5)2.06 (0.51-8.32)
8q24G>T0.384GG4 (19.0)16 (13.2)10.479
 rs6983267GT, TT17 (81.0)105 (86.8)0.65 (0.19-2.17)
8q24A>C0.162AA0 (0.0)2 (1.7)10.553
 rs1447295AC, CC21 (100.0)119 (98.3)0.98 (0.96-1.01)
8q24A>G0.162AA0 (0.0)5 (4.1)10.343
 rs4242382AG, GG21 (100.0)116 (95.9)0.96 (0.92-1.00)
8q24C>A0.155CC0 (0.0)4 (3.3)10.398
 rs4242384CA, AA21 (100.)117 (96.7)0.97 (0.94-1.00)
8q24T>G0.141TT0 (0.0)5 (4.1)10.343
 rs7837688TG, GG21 (100.0)116 (95.9)0.96 (0.92-1.00)
8q24A>G0.278AA, AG18 (85.7)113 (93.4)10.225
 rs16902094GG3 (14.3)8 (6.6)2.35 (0.57-9.71)
8q24T>C0.454TT, TC16 (76.2)99 (81.8)10.544
 rs445114CC5 (23.8)22 (18.2)1.41 (0.47-4.25)
8q24T>C0.304TT, TC19 (95.0)105 (87.5)10.329
 rs1456315CC1 (5.0)15 (12.5)0.37 (0.05-2.96)
8q24A>C0.254AA, AC17 (81.0)116 (95.9)10.010
 rs6983561CC4 (19.0)5 (4.1)5.45 (1.33-22.36)
8q24C>A0.261CC, CA17 (81.0)116 (95.9)10.010
 rs16901979AA4 (19.0)5 (4.1)5.46 (1.33-22.36)
8q24C>T0.261CC, CT17 (81.0)116 (95.9)10.010
 rs10505483TT4 (19.0)5 (4.1)5.46 (1.33-22.36)
8q24A>G0.292AA, AG17 (81.0)106 (87.6)10.409
 rs13252298GG4 (19.0)15 (12.4)1.66 (0.49-5.61)
8q24C>T0.340CC, CT17 (81.0)107 (89.2)10.286
 rs1016343TT4 (19.0)13 (10.8)1.94 (0.56-6.64)
8q24A>G0.391AA, AG12 (57.1)77 (63.6)10.570
 rs10505477GG9 (42.9)44 (36.4)1.31 (0.51-3.36)
8q24G>T0.261GG, GT17 (81.0)112 (92.6)10.089
 rs9642880TT4 (19.0)9 (7.4)2.93 (0.81-10.57)
8q24A>G0.465AA, AG19 (90.5)81 (66.9)10.029
 rs13281615GG2 (9.5)40 (33.1)0.21 (0.05-0.96)
8q24T>C0.170TT, TC21 (100.0)113 (94.2)10.256
 rs1562430CC0 (0.0)7 (5.8)0.94 (0.90-0.98)
8q24A>G0.278AA3 (14.3)7 (5.8)10.160
 rs7014346AG, GG18 (85.7)114 (94.2)0.37 (0.09-1.57)
MycC>T0.113CC, CT21 (100.0)120 (99.2)10.676
 rs4645957TT0 (0)1 (0.8)0.99 (0.98-1.01)
MycC>T0.150CC, CT20 (95.2)117 (98.3)10.369
 rs4645948TT1 (4.8)2 (1.7)2.93 (0.25-33.79)
MycT>C0.011TT21 (100.0)118 (97.5)10.466
 rs4645962TC, CC0 (0.0)3 (2.5)0.98 (0.95-1.01)
MycC>T0.302CC8 (42.1)55 (49.1)10.572
 rs4645943CT, TT11 (57.9)57 (50.9)1.33 (0.50-3.55)
MycC>T0.159CC11 (61.1)84 (73.7)10.270
 rs4645974CT, TT7 (38.9)30 (26.3)1.78 (0.63-5.02)

Data are expressed as relative risks.
Patients with the CC genotype were not found in this study.